Study backs PDE-4 inhibitor for psoriatic arthritis

Study backs PDE-4 inhibitor for psoriatic arthritis

The 505-person study randomised psoriatic arthritis patients who had failed prior treatment to either 20mg of apremilast twice daily, 30mg of apremilast twice daily or placebo. After 16 weeks, 28% of patients who received the 20mg dose had a 20% …

(Visited 3 times, 1 visits today)
1
Like
Save

Comments

Comments are disabled for this post.